Dear Sir/Madam, Please find the attached intimation under Regulation 57(4) of SEBI (LODR) Regulations, 2015. Kindly take the same on record and oblige. Thanking You.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Prism Medico and Pharmacy Ltd has informed BSE and MSE that, under Regulation 57(4) of SEBI's Listing Obligations and Disclosure Requirements, the company has not issued any non-convertible securities (such as NCDs or preference shares) for which interest, dividend, or principal payments would be due during the quarter from April 1, 2026 to June 30, 2026. This is a routine 'nil' compliance intimation, meaning the company has no upcoming debt-servicing obligations in the next quarter. The filing is signed by Director Davender Singh and addressed to both BSE (Scrip Code: 512217) and MSE (Symbol: PRISMMEDI).
This is a standard regulatory filing with no material impact on shareholders or the stock price. It simply confirms the company has no non-convertible security payment obligations in the upcoming quarter.